Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $220.00 Consensus PT from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has received a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $220.00.

A number of research analysts have commented on KRYS shares. Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in shares of Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after buying an additional 21,133 shares in the last quarter. Vanguard Group Inc. raised its holdings in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock worth $411,831,000 after purchasing an additional 6,600 shares during the period. Geode Capital Management LLC boosted its stake in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Finally, Hood River Capital Management LLC increased its position in shares of Krystal Biotech by 2.1% during the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company’s stock valued at $80,324,000 after purchasing an additional 10,622 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 2.3 %

Shares of NASDAQ:KRYS opened at $168.57 on Friday. The firm has a market cap of $4.87 billion, a PE ratio of 56.38 and a beta of 0.75. The company has a fifty day simple moving average of $174.73 and a 200 day simple moving average of $171.98. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the prior year, the business posted $0.30 EPS. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. As a group, equities research analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).